雷帕鸣价格多少

Toxic side effects have been reported, including fatal hepatic necrosis due to elevated sirolimus trough concentrations (i.e., above therapeutic levels). There have been reports of poor healing after transplant surgery, including fascial dehiscence, incisional hernia, and rupture of anastomotic sites (such as wounds, blood vessels, airways, ureters, biliary tracts, etc.). Spermia has also been reported in patients receiving rapamycin, and most patients improved when rapamycin was discontinued.

At the same time, this type of compound also has the potential to treat stroke, neurodegenerative diseases, Parkinson's syndrome, Alzheimer's disease, etc.

Rapamin oral solution is rapidly absorbed after administration, with the average time to peak after a single oral dose being approximately 1 hour; in renal transplant recipients, the average time to peak after multiple oral doses is approximately 2 hours. High-fat meals can increase the absorption of sirolimus, so it is recommended that oral rapamycin should be taken regularly with or without food. Patients must use rapamycin under the doctor's advice and must not take the medicine privately to avoid aggravating the condition.

Because rapamin has low nephrotoxicity, it can maintain long-term stability of renal function, and it can also reduce the incidence of tumors in transplant patients while suppressing immunity. It is generally believed that rapamycin binds to FKBP12, and the RAPA-FKBP12 complex binds to the mammalian target of rapamycin (mTOR), inhibiting the proliferation of T lymphocytes and B lymphocytes caused by various stimuli, causing cells to stay in the late G1 phase of the cell cycle, and preventing these cells from entering the S phase.

Rapamin oral solution is a new generation of immunosuppressant following the advent of cyclosporine A, mycophenolate mofetil and tacrolimus. It was launched in the United States and Europe in 1999 and in China at the end of 2003. In terms of price, according to Medical Travel, the product produced by Biocon in India is about $200. Biocon is India's first biotechnology company and its proprietary technology has been funded by the United States. If patients want to purchase medicine, please consult Medical Companion Travel.

Recommended related hot articles: /newsDetail/87031.html